The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Study Details
Study Description
Brief Summary
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: CMAB008
|
Drug: Infliximab
100mg/vial
|
Active Comparator: Remicade
|
Drug: Infliximab
100mg/vial
|
Outcome Measures
Primary Outcome Measures
- Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade [up to 1680 hours]
Secondary Outcome Measures
- Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade [up to 1680 hours]
- Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade [up to 1680 hours]
- Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade [up to 1680 hours]
- Total Frequency of AE/SAE Within the Whole Time of the Study [up to 1680 hours]
- Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected [up to 1680 hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy subject (male) between the ages of 18 and 45 years.
-
Subject with a body weight of ≥50 kg and ≤ 80 kg and a BMI between 19.0~26.0 kg/m2 (both inclusive);
-
Healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead electrocardiogram;
Exclusion Criteria:
-
Those who have surgered 4 weeks before signing the informed consent;
-
Those with mental, respiratory, cardiovascular, digestive, urinary, reproductive, skeletal and motor, blood, endocrine, nervous and other system diseases, or those with any previous immune diseases;
-
Those who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins, dietary supplements, etc.) and health care products within 4 weeks before signing the informed consent;
-
Those who accepted biological drugs within 6 months before signing the informed consent, or accepted the TNF monoconal antibody drugs;
-
Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum antibody is positive;
-
Either T cell immunospot test (T-SPOT) or antinuclear antibody is positive;
-
Those who have infected within 30 days before administration, or serious infection associated with hospitalisation and/or which required inrravenous antibiotics within 3 months before administration.
-
Vaccinated within 30 months before signing the informed conset, or plan to vaccinate during the trail;
-
Those who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior to the trail; those who have positive drug abuse test results;
-
Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 250ml per cup) every day;
-
Those who have a blood donation history of 400 ml within 3 months, or 200 ml within 1 month;
-
Those who have a history of drug or food allergy, or are known to be allergic to any component of the test drug or latex, etc.
-
Those who are addicted to smoking or smoke more than 10 cigarettes per day on average within 6 months before signing the informed consent;
-
Alcoholics or regular drinkers within 3 months before the trail, i.e. those who drink more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive;
-
Those who plan to donate sperm within 6 months after the adminstration of the test drug;
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Shanghai Xuhui Central Hospital | Shanghai | Shanghai | China | 200031 |
Sponsors and Collaborators
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMAB008HV-I